Humulin NPC, 100 me/ml suspension 3 ml cartridges 5 pcs

Type 2 diabetes, Type 1 diabetes

– Diabetes mellitus with indications for insulin therapy.
– Newly diagnosed diabetes mellitus.
– Pregnancy in type 2 diabetes mellitus (insulin-independent).

Indications

– Diabetes mellitus if there are indications for insulin therapy.
– Newly diagnosed diabetes mellitus.
– Pregnancy with type 2 diabetes mellitus (non-insulin dependent).

Special instructions

In case of damage or loss of the pen-injector or cartridge, it is recommended to have an insulin preparation with you (any replacement of insulin should be done with caution and only under the supervision of a physician) in a bottle and a syringe for administering the drug. Transferring a patient to another type of insulin or to an insulin preparation with a different trade name should occur under strict medical supervision. Changes in insulin activity, insulin type (eg, M3, NPH), type (porcine, human insulin, human insulin analog), or production method (DNA recombinant insulin or animal insulin) may require dosage adjustments.

The need for dose adjustment may be required as early as the first administration of a human insulin product after an animal insulin product or gradually over several weeks or months after the transfer. The need for insulin may be reduced if there is insufficient function of the adrenal glands, pituitary gland or thyroid gland, or with renal or liver failure. With some illnesses or emotional stress, the need for insulin may increase.

Dose adjustments may also be required if you increase physical activity or change your usual diet.

Symptoms that are precursors of hypoglycemia during the administration of human insulin in some patients may be less pronounced or different from those observed during the administration of animal insulin. When blood glucose levels are normalized, for example as a result of intensive insulin therapy, all or some of the symptoms that are precursors of hypoglycemia may disappear, of which patients should be informed. Symptoms that predict hypoglycemia may change or be less pronounced with long-term diabetes mellitus, diabetic neuropathy, or with the simultaneous use of beta-blockers.

In some cases, local allergic reactions may be caused by reasons unrelated to the action of the drug, for example, skin irritation by the cleansing agent or improper injection.

In rare cases of systemic allergic reactions, immediate treatment is required. Sometimes it may be necessary to change insulin or carry out desensitization.

Insulin requirements may be reduced in liver failure. Insulin requirements may be reduced in renal failure.

Impact on the ability to drive vehicles and operate machinery:

During hypoglycemia, the patient’s ability to concentrate may deteriorate and the speed of psychomotor reactions may decrease. This can be dangerous in situations where these abilities are especially needed (driving a car or operating machinery). Patients should be advised to take precautions to avoid hypoglycemia while driving. This is especially important for patients with mild or absent warning signs of hypoglycemia or who frequently develop hypoglycemia. In such cases, the doctor should evaluate the advisability of the patient driving a car.

Active ingredient

Insulin-isophane human genetically engineered

Composition

1 ml of suspension for subcutaneous administration contains:

active substance:

insulin isophane (human genetically engineered) 100 IU,

excipients:

metacresol,

glycerol,

phenol,

protamine sulfate,

sodium hydrogen phosphate,

zinc oxide,

water for injections,

hydrochloric acid 10% and sodium hydroxide solution 10% (to create the required pH level).

Contraindications

– Hypoglycemia.

– Hypersensitivity to insulin or to one of the components of the drug.

Side Effects

Side effect associated with the main effect of the drug: hypoglycemia. Severe hypoglycemia can lead to loss of consciousness and (in exceptional cases) death.

Allergic reactions: local allergic reactions are possible – hyperemia, swelling or itching at the injection site (usually disappear within a period of several days to several weeks); systemic allergic reactions (occur less frequently, but are more serious) – generalized itching, difficulty breathing, shortness of breath, decreased blood pressure, increased heart rate, increased sweating. Severe cases of systemic allergic reactions can be life-threatening.

Other: the likelihood of developing lipodystrophy is minimal.

Interaction

The hypoglycemic effect of Humulin NPH is reduced by oral contraceptives, corticosteroids, thyroid hormone preparations, thiazide diuretics, diazoxide, and tricyclic antidepressants.

The hypoglycemic effect of Humulin NPH is enhanced by oral hypoglycemic drugs, salicylates (for example, acetylsalicylic acid), sulfonamides, MAO inhibitors, beta-blockers, ethanol and ethanol-containing drugs.

Beta-blockers, clonidine, reserpine can mask the symptoms of hypoglycemia.

Pharmaceutical interactions

The effects that occur when human insulin is mixed with animal insulins or human insulin from other manufacturers have not been studied.

Overdose

Symptoms: hypoglycemia, accompanied by lethargy, increased sweating, tachycardia, pale skin, headache, trembling, vomiting, confusion. Under certain conditions, such as long-term diabetes or intensive control of diabetes, the warning symptoms of hypoglycemia may change.

Treatment: Mild hypoglycemia can usually be treated with oral glucose (dextrose) or sugar. Adjustments to your insulin dose, diet, or physical activity may be necessary. Correction of moderate hypoglycemia can be carried out using intramuscular or subcutaneous administration of glucagon followed by oral carbohydrates.

Severe conditions of hypoglycemia, accompanied by coma, convulsions or neurological disorders, are treated with intramuscular or subcutaneous administration of glucagon or intravenous administration of a concentrated solution of glucose (dextrose). After regaining consciousness, the patient must be given food rich in carbohydrates to avoid re-development of hypoglycemia.

Manufacturer

Lilly France, France